Doctors at the [b]University of Arizona Cancer Centre at St Joseph's Hospital and Medical Centre[/b] have reported that a new treatment for ovarian cancer can improve response rates and prolong the time until cancers recur. In addition, [s]News-Medical[/s] reports, this breakthrough showed a trend in improving survival although these data are not yet mature. Trebananib is a first-in-class peptide-Fc fusion protein that targets angiogenesis (the growth of new blood vessels into cancerous tumours). This is very different mechanism of action than other agents that also effect angiogenesis by inhibiting vascular endothelial growth factor. But, the report notes, neither agent has shown a definitive increase in survival at this point.
[link url=http://www.news-medical.net/news/20140620/New-treatment-for-ovarian-cancer-can-improve-response-rates.aspx]Full News-Medical report[/link]
[link url=http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70244-X/abstract]Lancet Oncology article summary[/link]